Trial Profile
Multicenter, randomized, double-blind placebo in Phase I to evaluate safety of oral ALK lyophilized mite in children
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors ALK-Abello
- 08 Apr 2022 Status changed from recruiting to completed.
- 29 Aug 2011 New trial record